Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation (CRISTEL)

11. Mai 2026 aktualisiert von: Hopital Foch
The objective of this research is to obtain standardized and independent data on the number of pregnancies occurring in France and their follow-up up to 1 year postpartum (or post-pregnancy termination). This study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will enable the dissemination of clear and up-to-date information to the medical community, thus contributing to better patient counseling and, more broadly, to couples. They will also serve to issue recommendations to optimize the planning and follow-up of pregnancies in women with solid organ transplants. Finally, this initiative aims to promote clinical research on pregnancies.

Studienübersicht

Status

Noch keine Rekrutierung

Intervention / Behandlung

Detaillierte Beschreibung

According to North American and Australian registries, pregnancy is both a joyful and high-risk event for women who have received a solid organ transplant. Typically, a transplanted woman has a probability comparable to that of the general population of giving birth to a live infant, but she is likely to deliver prematurely (median gestational age: 32 weeks), to have a growth-restricted baby (median birth weight around 2.3 kg), and often in a context of preeclampsia (in at least 30% of cases)(1).

Today, these are the data shared with patients planning a pregnancy, despite uncertainty as to their accuracy and applicability in France or even Europe.

Among the unknowns that remain despite these registry data, the following should be noted:

Uncertainty about the level of pregnancy planning in this specific context: What proportion of women of childbearing age have been informed of the possibility of becoming pregnant, of the associated risks, and of necessary precautions (e.g., stopping mycophenolate mofetil at least 6 weeks before conception);

Variability in the information provided from one center to another, due to the absence of a national, consensus-based document addressing fertility and contraception in the post-transplantation setting;

Monitoring frequency specific to the graft, especially regarding exposure to immunosuppressive drugs (and consequently actual exposure to calcineurin inhibitors, the cornerstone of anti-rejection therapy, whose residual blood concentration varies from the second trimester onward)(2);

The true risk of preeclampsia, at a time when diagnosis can be refined by measuring levels of placental-derived anti-angiogenic factors in maternal serum (sFlt-1/PlGF ratio)(3), and by uterine artery Doppler;

The incidence of de novo anti-HLA immunization (HLA antigens expressed by the fetus and inherited from the father), which can now be assessed using the Luminex technique(4);

Maternal morbidity: What is the impact of pregnancy on graft function? Conversely, how does renal function influence pregnancy outcomes, regardless of the transplanted organ?

Infant morbidity in the short and medium term.

To establish these data and to provide accurate information to patients, we aim to conduct a study among pregnant women who have undergone solid organ transplantation (kidney, heart, lung, liver, or pancreas). The objective of this research is to collect standardized and independent data on the number of pregnancies occurring in France and to monitor them up to one year postpartum (or after pregnancy termination).

The study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will help disseminate clear and up-to-date information to the medical community, thus improving patient counseling and, more broadly, support for couples. They will also serve to develop recommendations to optimize the planning and management of pregnancies in women with solid organ transplants.

Finally, this initiative aims to promote clinical research on pregnancy in the context of transplantation, particularly through clinical trials and the development of biobanks.

Studientyp

Interventionell

Einschreibung (Geschätzt)

2000

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Female patient aged 18 years or older and of childbearing age
  • Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney)
  • Has a positive blood beta-hCG test result > 5 IU/L ("positive")
  • Has signed an informed consent form
  • Affiliated with a health insurance plan

Exclusion Criteria:

  • Patient deprived of liberty or under legal guardianship
  • Patient refuses to participate in the study

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Screening
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Sonstiges: Adult female patients who have received a solid organ transplant
Adult female patients who have received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney), and who present with a positive beta-hCG blood test result (defined by a threshold of 5 IU/L) in one of the participating centers, or who are planning a pregnancy, will initially be identified.

Two optional (non-mandatory) biological samples may be collected as part of this study:

A 2 mL venous blood sample may be taken during a routine prenatal follow-up visit (around 30 weeks of gestation) in order to analyze the preeclampsia biomarker (sFlt-1/PlGF ratio), whenever preeclampsia is suspected.

A 5 mL sample from cord blood may be collected after delivery to analyze, in the newborn, the complete blood count, white blood cell differential, lymphocyte phenotyping (T CD3+, CD19+CD20+, and NK CD46+), and immunoglobulin levels (G, A, and M for humoral immunity, and E for allergy-related function).

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
Zeitfenster: Annually over the 10-year study period
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
Annually over the 10-year study period

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Rate of preeclampsia
Zeitfenster: Through study completion, an average of 1 year
Rate of preeclampsia
Through study completion, an average of 1 year
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
Zeitfenster: 3 months and 12 months postopartum
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
3 months and 12 months postopartum
Live birth rate among transplanted mothers from the onset of pregnancy.
Zeitfenster: through study completion, an average of 1 year
Live birth rate among transplanted mothers from the onset of pregnancy.
through study completion, an average of 1 year
Trajectory of serum creatinine levels
Zeitfenster: During pregnancy (up to 40 weeks if gestation)
Trajectory of serum creatinine levels
During pregnancy (up to 40 weeks if gestation)
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
Zeitfenster: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
Zeitfenster: Day of delivery: Perioperative/Periprocedural
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
Day of delivery: Perioperative/Periprocedural
Birth weight of the newborn (in grams)
Zeitfenster: day of delivery
Birth weight of the newborn (in grams)
day of delivery
Rate of spontaneous miscarriage
Zeitfenster: Through study completion, an average of 1 year
Rate of spontaneous miscarriage
Through study completion, an average of 1 year
Rate of cesarean section
Zeitfenster: Through study completion, an average of 1 year
Rate of cesarean section
Through study completion, an average of 1 year
Rate of prematurity
Zeitfenster: Through study completion, an average of 1 year
Rate of prematurity
Through study completion, an average of 1 year
Rate of intrauterine growth restriction
Zeitfenster: Through study completion, an average of 1 year
Rate of intrauterine growth restriction
Through study completion, an average of 1 year
the duration of hospital stay for both the mother and the newborn
Zeitfenster: Through study completion, an average of 1 year
the duration of hospital stay for both the mother and the newborn
Through study completion, an average of 1 year
incidence of biopsy-proven acute rejection up to 12 months postpartum;
Zeitfenster: up to 12 months postpartum;
incidence of biopsy-proven acute rejection up to 12 months postpartum;
up to 12 months postpartum;
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
Zeitfenster: 3 months and 12 months postoartum
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
3 months and 12 months postoartum
Trajectory of proteinuria (protein-to-creatinine ratio)
Zeitfenster: During pregnancy (up to 40 weeks if gestation)
Trajectory of proteinuria (protein-to-creatinine ratio)
During pregnancy (up to 40 weeks if gestation)
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
Zeitfenster: During pregnancy (up to 40 weeks if gestation)
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
During pregnancy (up to 40 weeks if gestation)
Trajectory of anti-angiogenic factors during pregnancy
Zeitfenster: During pregnancy (up to 40 weeks if gestation)
Trajectory of anti-angiogenic factors during pregnancy
During pregnancy (up to 40 weeks if gestation)
Rate of maternal complications and hospitalizations before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
Zeitfenster: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Rate of maternal hospitalizations before delivery and in the postpartum period
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Apgar score
Zeitfenster: day of delivery
Apgar score
day of delivery
Proportion of growth-restricted
Zeitfenster: day of delivery and up 3 month postpartum
Proportion of growth-restricted
day of delivery and up 3 month postpartum
Incidence of neonatal complications before the third month of life
Zeitfenster: day of delivery and up 3 month postpartum
Incidence of neonatal complications before the third month of life
day of delivery and up 3 month postpartum

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Alexandre Pr Hertig, MED, Foch Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. September 2026

Primärer Abschluss (Geschätzt)

1. September 2036

Studienabschluss (Geschätzt)

1. September 2036

Studienanmeldedaten

Zuerst eingereicht

22. September 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. Mai 2026

Zuerst gepostet (Tatsächlich)

18. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren